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Identity 
Other names: ATFX; FLJ34666; HMFN0395 
HGNC (Hugo): ATF5 
Location: 19q13.33 
Local order: Refer to mapping diagram. 
DNA/RNA 
Description 
The ATF5 gene spans a total genomic size of 5219 
bases and is composed of four exons. 
Transcription 
The human ATF5 transcript is 2268 bp in size 
(NM_012068.4) and contains 4 exons. Exon 1 and 2 
are non-coding exons and the size of open reading 
frame is 849 bp. 
Protein 
Description 
ATF5 consists of 282 amino acid with MW of 30.69 
kDa (NCBI reference sequence NP_036200.2). 
Expression 
Northern blot analysis revealed ubiquitous expression 
of ATF5, with highest levels in liver, lung, adipose 
tissue, heart, and skeletal muscle. 
Localisation 
Nucleus and cytoplasm. 
 
Mapping diagram. Base on Human Mar. 2006 (NCBI36/hg18) Assembly. 
 
 
DNA structure diagram. Relative size of the 4 exons of ATF5. Exon 1 and 2 are untranslated exons (NCBI reference sequence 
NM_012068.4). Blue area is non-coding region and pink is coding region. 
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Protein structure diagram. 
 
Function 
ATF5 is a member of basic-region leucine zipper 
(bZIP) proteins family which binds the cAMP response 
element (CRE) consensus sequence: 
5'GTGACGT(C/A)(G/A). This sequence is present in 
many viral and cellular promoters. ATF within or 
between subgroups can form homo- or hetero-dimer 
through the bZIP domain and the dimer can then bind
to the DNA through the basic-motif and function as a 
transcription factor. Recently, another novel ATF5 
consensus DNA binding sequence (CYTCTYCCTTW) 
was found in C6 glioma and MCF7 using a cyclic 
amplification and selection of targets (CASTing) 
approach (Li et al., 2009).  
ATF5 is linked to many cellular function including cell 
cycle progression, metabolite homeostasis (Al Sarraj et 
al., 2005; Watatani et al., 2007), cellular differentiation 
and apoptosis. It involves in the proliferation and 
differentiation of neural cells (Angelastro et al., 2003; 
Angelastro et al., 2005; Mason et al., 2005) and has 
been shown to take part in the skeletal development of 
mouse limb (Shinomura et al., 2006; Satake at al., 
2009). Data from various groups also suggested that 
ATF5 can function as anti-apoptotic factor (Devireddy 
et al., 2001; Persengiev et al., 2002; Nishioka et al., 
2009). 
Coimmunoprecipitation and GST pull-down analyses 
confirmed the association of the C-terminal bZIP motif 
of ATF5 with the PRL-1 PTPase domain and adjacent 
residues of PTP4A1 in vitro. SDS-PAGE analysis 
showed that PRL-1 dephosphorylates ATF5 in vitro 
(Peters et al., 2001).  
ATF5 has been shown to interact with various proteins 
including Cyclin D3 (Liu et al., 2004), GABAB 
receptors (White et al., 2000), HTLV-1 viral protein 
Tax (Forgacs et al., 2005), E2 ubiguitin-conjugating 
enzyme Cdc34, PRL-1 and DISC1 (Morris et al., 2003; 
Fujii et al., 2007; Tomppo et al., 2009). It is a target of 
Cdc34-dependent ubiquitin-mediated proteolysis (Pati 
et al., 1999). Study indicates that during stress 
condition, eIF2 is phosphorylated and subsequently 
direct ATF5 translation in cell (Watatani et al., 2008; 
Zhou et al., 2008). Recent study of the promoter of 
ATF5 also suggested that its transcription is regulated 
by EBF1 (Wei et al., 2010). 
Homology 
ATF5 gene is highly conserved in mammals. Protein 
identity percentage of human ATF5 compared with 
chimpanzee, cow, mouse, and rat is 98.9, 88.0, 87.5










ATF5 is showed to be overexpressed in various cancers 
by TMA (tissue microarray) that includes breast cancer, 
glioblastomas, adenocarcinomas, transitional cell 
carcinomas, squamous cell carcinomas and metastatic 
carcinomas of various origin (Monaco et al., 2007). 
However, in hepatocellular carcinoma, ATF5 
expression is down-regulated, suggesting that role of 
ATF5 in tumor is highly depending on the tumor type. 
Glioma 
Note 
ATF5 has been shown to be highly expressed in 
perinecrotic palisades, the most aggressive forms of 
malignant gliomas. In a study of 28 tumors without 
perinecrotic palisades, the level of ATF5 expression 
together with 4 other genes, negatively correlated with
time of patient survival. Interference of ATF5 
expression in glioma cell lines causes apoptosis but not 
in cultured astrocytes. These findings suggested that 

















A study has showed that ATF5 is down-regulated in 60 
out of 77 cases in HCC, as in contrast to adult normal 
liver where expression of ATF5 is particularly high. 
Gene expression profiling was also done by ectopic re-
expression of ATF5 suggesting cell cycle, actin 
skeleton regulation, MAPK signaling and focal 
adhesion are the pathways modulated by ATF5. These 
findings suggested that ATF5 down regulation may 
contribute to the development of HCC. The inactivation 
mechanisms of ATF5 involve epigenetic silencing and
chromosome copy number loss. 
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